CytomX Therapeutics, Inc. Quarterly Deferred Tax Assets, Valuation Allowance in USD from Q4 2013 to Q4 2023

Taxonomy & unit
us-gaap: USD
Description
Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.
Summary
CytomX Therapeutics, Inc. quarterly Deferred Tax Assets, Valuation Allowance history and growth rate from Q4 2013 to Q4 2023.
  • CytomX Therapeutics, Inc. Deferred Tax Assets, Valuation Allowance for the quarter ending December 31, 2023 was $175M, a 5.67% increase year-over-year.
Deferred Tax Assets, Valuation Allowance, Quarterly (USD)
Deferred Tax Assets, Valuation Allowance, YoY Quarterly Growth (%)
Period Value YoY Chg Change % Date Report Filed
Q4 2023 $175M +$9.42M +5.67% Dec 31, 2023 10-K 2024-03-11
Q4 2022 $166M +$22.7M +15.8% Dec 31, 2022 10-K 2024-03-11
Q4 2021 $143M +$24.8M +20.9% Dec 31, 2021 10-K 2023-03-27
Q4 2020 $119M +$9.37M +8.58% Dec 31, 2020 10-K/A 2023-03-27
Q4 2019 $109M +$22.7M +26.3% Dec 31, 2019 10-K 2021-02-24
Q4 2018 $86.5M +$35.7M +70.2% Dec 31, 2018 10-K 2021-02-24
Q4 2017 $50.8M +$4.65M +10.1% Dec 31, 2017 10-K 2020-02-27
Q4 2016 $46.1M +$21.1M +84.2% Dec 31, 2016 10-K 2019-02-27
Q4 2015 $25M -$969K -3.73% Dec 31, 2015 10-K 2018-03-07
Q4 2014 $26M +$10.9M +71.9% Dec 31, 2014 10-K 2017-03-02
Q4 2013 $15.1M Dec 31, 2013 10-K 2016-03-07
* An asterisk sign (*) next to the value indicates that the value is likely invalid.